NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NAMS
NewAmsterdam Pharma Company N.V. (NAMS) EV/Sales
As of 16 October 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a EV/Sales of 254×. Over the past ten years it has ranged from 0.0× (December 2023) to 552× (July 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 156× | 347.61% |
| FY2024 | 34.9× | 23.60% |
| FY2023 | 28.2× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 498× | 244.80% |
| Mar 2026 | 144× | (7.59%) |
| Dec 2025 | 156× | 105.50% |
| Sep 2025 | 76.0× | 245.73% |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| ADMA ADMA Biologics Inc compare | 4.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| BEAM Beam Therapeutics Inc. compare | 8.9× |
| PGEN Precigen, Inc. compare | 27.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| NAMS NewAmsterdam Pharma Company N.V. | 254× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)